H101 Combined With Camrelizumab for Recurrent Cervical Cancer
NCT05234905
·
clinicaltrials.gov ↗
PHASE2
Phase
UNKNOWN
Status
55
Enrollment
OTHER
Sponsor class
Conditions
Uterine Cervical Neoplasms
Oncolytic Virotherapy
Camrelizumab
Interventions
DRUG:
Recombinant human adenovirus type 5＋Camrelizumab
Sponsor
Zhejiang Cancer Hospital